"Linagliptin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.
| Descriptor ID |
D000069476
|
| MeSH Number(s) |
D03.633.100.759.562 D03.633.100.786.563
|
| Concept/Terms |
Linagliptin- Linagliptin
- (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
- 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-
BI 1356- BI 1356
- 1356, BI
- BI1356
- BI-1356
|
Below are MeSH descriptors whose meaning is more general than "Linagliptin".
Below are MeSH descriptors whose meaning is more specific than "Linagliptin".
This graph shows the total number of publications written about "Linagliptin" by people in this website by year, and whether "Linagliptin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2017 | 6 | 1 | 7 |
| 2018 | 4 | 2 | 6 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Linagliptin" by people in Profiles.
-
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. ChemMedChem. 2021 05 06; 16(9):1425-1426.
-
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019 01 15; 139(3):351-361.
-
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019 01 01; 321(1):69-79.
-
Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. Diabetes Obes Metab. 2019 04; 21(4):837-843.
-
Risk of hypoglycaemia in people aged =65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. Int J Clin Pract. 2018 Oct; 72(10):e13240.
-
Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity. Diabetes Obes Metab. 2018 12; 20(12):2911-2918.
-
Effect of Linagliptin on Incretin-axis and Glycaemic Variability in T1DM. J Assoc Physicians India. 2018 Jul; 66(7):28-32.
-
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. Pharmacoepidemiol Drug Saf. 2018 06; 27(6):660-667.
-
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018 03 14; 17(1):39.
-
A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial. J Am Med Dir Assoc. 2018 05; 19(5):399-404.e3.